AS

Ajay Sheelu

Active Director Director DIN 11848296
DIN 11848296 First appointment Jul 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Ajay Sheelu

Ajay Sheelu is a Director at Med Relief Pharmaceuticals Private Limited (since 2026).

DIN 11848296
Primary Designation Director
First Appointment 24 Jul 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 Jul 20262026Active

Board colleagues of Ajay Sheelu

NameDINCompanyDesignation
Himanshu PalMed Relief Pharmaceuticals Private LimitedIndividual Subscriber
Kamal Kumar11848295Med Relief Pharmaceuticals Private LimitedDirector
Priyanshu PalMed Relief Pharmaceuticals Private LimitedIndividual Subscriber

Directorship timeline

Open interactive timeline →
Med Relief Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Ajay Sheelu

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ajay Sheelu

Ajay Sheelu currently holds 1 directorship: Med Relief Pharmaceuticals Private Limited (Director, since 24 Jul 2026).

Ajay Sheelu was first appointed on 24 Jul 2026 as Director at Med Relief Pharmaceuticals Private Limited.

The current boards of Ajay Sheelu's companies include Himanshu Pal (Med Relief Pharmaceuticals Private Limited), Kamal Kumar (Med Relief Pharmaceuticals Private Limited), Priyanshu Pal (Med Relief Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available